BCL2 and non-small cell lung carcinoma: In non-small cell lung cancer, SSD and GEFITINIB are combined to reduce the expressions of P-Stat3 and BCL2, indicating that SSD can inhibit the activation of the P-Stat3/BCL2 signaling pathway induced by gefitinib and inhibit the resistance of gefitinib in cancer[42].